Market Overview

UPDATE: Morgan Stanley Initiates AbbVie at Equal-Weight; Heavy Reliance on Humira

Related ABBV
AbbVie Inc Spikes On Reported End-Run Around Inversion Rules
Inversion Crackdown Leaves Several Deals In Limbo
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

Morgan Stanley initiated coverage on AbbVie (NYSE: ABBV) with an Equal-weight rating and a $36 price target.

Morgan Stanley noted, "AbbVie (ABBV) biopharma separated from Abbott. We are EW given heavy reliance on Humira and 6% EV/EBITDA premium to global median, offset by attractive yield. Our $36 PT is based on 4.5% yield (assuming div is boosted 2.5% in Dec '13 to $1.64). … AbbVie generates the majority of its $18B in annual revenues from biologicals, including $9B from Humira, a self-injectable drug for arthritis and other autoimmune disorders. It has a highly experienced mgmt team with a strong track record. We project FCF of $5B+ to support $2.5B+ div and external deals to boost pipeline."

AbbVie closed at $35.12 on Wednesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsOutperform
Jul 2014UBSUpgradesNeutralBuy
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters